Association of antibody responses to the conserved Plasmodium falciparum merozoite surface protein 5 with protection against clinical malaria

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Perraut, Ronald ^a   Joos, Charlotte ^a,b   Sokhna, Cheikh ^c   Polson, Hannah E J ^b   Trape, Jean François ^c   Tall, Adama ^a   Marrama, Laurence ^a   Mercereau Puijalon, Odile ^b   Richard, Vincent ^a   Longacre, Shirley ^b  

^a INSTITUT PASTEUR DE DAKAR   (Senegal)

^b INSTITUT PASTEUR   (France)

^c INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (Senegal)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 5; MEROZOITE SURFACE PROTEIN 5 ANTIBODY; PARASITE ANTIGEN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; PROTOZOON ANTIBODY;

ADULT; AGE DISTRIBUTION; ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ANTIGEN ANTIBODY REACTION; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; COMMUNITY ASSESSMENT; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC CONSERVATION; HEALTH SURVEY; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSURVEILLANCE; INCIDENCE; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; OBSERVATIONAL STUDY; PLASMODIUM FALCIPARUM; RESPIRATORY BURST; SEROPREVALENCE; ADOLESCENT; AGED; ANTIBODY PRODUCTION; BLOOD; CHILD; CROSS-SECTIONAL STUDY; IMMUNOLOGY; MALARIA, FALCIPARUM; MIDDLE AGED; PRESCHOOL CHILD; PROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, PROTOZOAN; ANTIBODY FORMATION; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PLASMODIUM FALCIPARUM; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; YOUNG ADULT;

EID: 84904697660     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101737     Document Type: Article

References (43)

1. WHO (2012) WHO World Malaria Report 2012. Available: http://wwwwhoint/ malaria/publications/world-malaria-report-2012/en/.
2. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, et al. (2009) Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361: 455-467.
3. Noranate N, Durand R, Tall A, Marrama L, Spiegel A, et al. (2007) Rapid dissemination of Plasmodium falciparum drug resistance despite strictly controlled antimalarial use. PLoS One 2: e139.
4. Trape JF, Tall A, Diagne N, Ndiath O, Ly AB, et al. (2011) Malaria morbidity and pyrethroid resistance after the introduction of insecticide-treated bednets and artemisinin-based combination therapies: a longitudinal study. Lancet Infect Dis.
5. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P (1990) Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med 172: 1633-1641.
6. Cohen S, McGregor IA, Carrington S (1961) Gamma-globulin and acquired immunity to human malaria. Nature 192: 733-737.
7. Cowman AF, Crabb BS (2006) Invasion of red blood cells by malaria parasites. Cell 124: 755-766. (Pubitemid 43261450)
8. Riley EM, Stewart VA (2013) Immune mechanisms in malaria: new insights in vaccine development. Nat Med 19: 168-178.
9. Chitarra V, Holm I, Bentley GA, Petres S, Longacre S (1999) The crystal structure of C-terminal merozoite surface protein 1 at 1.8 A resolution, a highly protective malaria vaccine candidate. Mol Cell 3: 457-464. (Pubitemid 29292602)
10. Pizarro JC, Chitarra V, Verger D, Holm I, Petres S, et al. (2003) Crystal structure of a Fab complex formed with PfMSP1-19, the C-terminal fragment of merozoite surface protein 1 from Plasmodium falciparum: a malaria vaccine candidate. J Mol Biol 328: 1091-1103. (Pubitemid 36506876)
11. O'Donnell RA, de Koning-Ward TF, Burt RA, Bockarie M, Reeder JC, et al. (2001) Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. J Exp Med 193: 1403-1412. (Pubitemid 32565969)
12. Dodoo D, Aikins A, Kusi KA, Lamptey H, Remarque E, et al. (2008) Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children. Malar J 7: 142.
13. Perraut R, Marrama L, Diouf B, Fontenille D, Tall A, et al. (2003) Distinct surrogate markers for protection against Plasmodium falciparum infection and clinical malaria identified in a Senegalese community after radical drug cure. J Infect Dis 188: 1940-1950. (Pubitemid 38064881)
14. Perraut R, Marrama L, Diouf B, Sokhna C, Tall A, et al. (2005) Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village. J Infect Dis 191: 264-271. (Pubitemid 40096385)
15. McCarthy JS, Marjason J, Elliott S, Fahey P, Bang G, et al. (2011) A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide(R) ISA 720. PLoS One 6: e24413.
16. Roussilhon C, Oeuvray C, Muller-Graf C, Tall A, Rogier C, et al. (2007) Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. PLoS Med 4: e320.
17. Richards JS, Arumugam TU, Reiling L, Healer J, Hodder AN, et al. (2013) Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development. J Immunol 191: 795-809.
18. Marshall VM, Tieqiao W, Coppel RL (1998) Close linkage of three merozoite surface protein genes on chromosome 2 of Plasmodium falciparum. Mol Biochem Parasitol 94: 13-25. (Pubitemid 28345145)
19. Polson HE, Conway DJ, Fandeur T, Mercereau-Puijalon O, Longacre S (2005) Gene polymorphism of Plasmodium falciparum merozoite surface proteins 4 and 5. Mol Biochem Parasitol 142: 110-115. (Pubitemid 40720134)
20. Wu T, Black CG, Wang L, Hibbs AR, Coppel RL (1999) Lack of sequence diversity in the gene encoding merozoite surface protein 5 of Plasmodium falciparum. Mol Biochem Parasitol 103: 243-250. (Pubitemid 29469776)
21. Woodberry T, Minigo G, Piera KA, Hanley JC, de Silva HD, et al. (2008) Antibodies to Plasmodium falciparum and Plasmodium vivax merozoite surface protein 5 in Indonesia: species-specific and cross-reactive responses. J Infect Dis 198: 134-142. (Pubitemid 351920300)
22. Bonnefoy S, Guillotte M, Langsley G, Mercereau-Puijalon O (1992) Plasmodium falciparum: characterization of gene R45 encoding a trophozoite antigen containing a central block of six amino acid repeats. Exp Parasitol 74: 441-451.
23. Trape JF, Rogier C, Konate L, Diagne N, Bouganali H, et al. (1994) The Dielmo project: a longitudinal study of natural malaria infection and the mechanisms of protective immunity in a community living in a holoendemic area of Senegal. Am J Trop Med Hyg 51: 123-137. (Pubitemid 24324732)
24. Joos C, Marrama L, Polson HE, Corre S, Diatta AM, et al. (2010) Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum antibodies. PLoS One 5: e9871.
25. Fontenille D, Lochouarn L, Diatta M, Sokhna C, Dia I, et al. (1997) Four years' entomological study of the transmission of seasonal malaria in Senegal and the bionomics of Anopheles gambiae and A. arabiensis. Trans R Soc Trop Med Hyg 91: 647-652. (Pubitemid 28019904)
26. Trape JF, Rogier C (1996) Combating malaria morbidity and mortality by reducing transmission. Parasitol Today 12: 236-240.
27. Trape JF (1985) Rapid evaluation of malaria parasite density and standardization of thick smear examination for epidemiological investigations. Trans R Soc Trop Med Hyg 79: 181-184.
28. Trape JF, Tall A, Sokhna C, Ly AB, Diagne N, et al. (2014) The rise and fall of malaria in a west African rural community, Dielmo, Senegal, from 1990 to 2012: a 22 year longitudinal study. Lancet Infect Dis 14: 476-488.
29. Rogier C, Commenges D, Trape JF (1996) Evidence for an age-dependent pyrogenic threshold of Plasmodium falciparum parasitemia in highly endemic populations. Am J Trop Med Hyg 54: 613-619. (Pubitemid 26238832)
30. Roucher C, Rogier C, Dieye-Ba F, Sokhna C, Tall A, et al. (2012) Changing malaria epidemiology and diagnostic criteria for Plasmodium falciparum clinical malaria. PLoS One 7: e46188.
31. Holm I, Nato F, Mendis KN, Longacre S (1997) Characterization of C-terminal merozoite surface protein-1 baculovirus recombinant proteins from Plasmodium vivax and Plasmodium cynomolgi as recognized by the natural anti-parasite immune response. Molec Biochem Parasitol 89: 313-319. (Pubitemid 27435102)
32. Bonnet S, Petres S, Holm I, Fontaine T, Rosario S, et al. (2006) Soluble and glyco-lipid modified baculovirus Plasmodium falciparum C-terminal merozoite surface protein 1, two forms of a leading malaria vaccine candidate. Vaccine 24: 5997-6008. (Pubitemid 44080361)
33. Aribot G, Rogier C, Sarthou JL, Balde AT, Trape JF, et al. (1996) Pattern of immunoglobulin isotype response to Plasmodium falciparum blood-stage antigens in individuals living in a holoendemic area of Senegal (Dielmo, West Africa). Am J Trop Med Hyg 54: 449-457.
34. Perraut R, Guillotte M, Drame I, Diouf B, Molez JF, et al. (2002) Evaluation of anti-Plasmodium falciparum antibodies in Senegalese adults using different types of crude extracts from various strains of parasite. Mic Infect 4: 31-35. (Pubitemid 34127988)
35. NGuer CM, Diallo TO, Diouf A, Tall A, Dièye A, et al. (1997) Plasmodium falciparum- and merozoite surface protein 1-specific antibody isotype balance in immune Senegalese adults. Infect Immun 65: 4873-4876.
36. Perraut R, Mercereau-Puijalon O, Diouf B, Tall A, Guillotte M, et al. (2000) Seasonal fluctuation of antibody levels to Plasmodium falciparum parasitized red blood cell-associated antigens in two Senegalese villages with different transmission conditions. Am J Trop Med Hyg 62: 746-751. (Pubitemid 32281498)
37. Perraut R, Morales-Betoulle S, Le Scanf C, Bourreau E, Guillotte M, et al. (2000) Evaluation of immunogenicity and protective efficacy of carrier-free Plasmodium falciparum R23 antigen in pre-exposed Saimiri sciureus monkeys. Vaccine 19: 59-67. (Pubitemid 30618955)
38. Rogier C, Trape JF (1993) Malaria attacks in children exposed to high transmission: who is protected? Trans R Soc Trop Med Hyg 87: 245-246.
39. Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, et al. (2002) A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis 185: 820-827. (Pubitemid 34226210)
40. Fluck C, Schopflin S, Smith T, Genton B, Alpers MP, et al. (2007) Effect of the malaria vaccine Combination B on merozoite surface antigen 2 diversity. Infect Genet Evol 7: 44-51. (Pubitemid 44882893)
41. Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Ouattara A, et al. (2011) A field trial to assess a blood-stage malaria vaccine. N Engl J Med 365: 1004-1013.
42. Garraud O, Mahanty S, Perraut R (2003) Malaria-specific antibody subclasses in immune individuals: a key source of information for vaccine design. Trends Immunol 24: 30-35. (Pubitemid 35469133)
43. Groux H, Gysin J (1990) Opsonization as an effector mechanism in human protection against asexual blood stages of Plasmodium falciparum: functional role of IgG subclasses. Res Immunol 141: 529-542. (Pubitemid 20377037)